Division of Gastroenterology

Publications 2004-2010

Dr. David Armstrong

  1. Hunt RH, Armstrong D, Yaghoobi M, James C. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther. 2010; 31: 648-57
  2. Verdu EF, Armstrong D, Murray JA. Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity. Am J Gastroenterol. 2009; 104: 1587-94.
  3. Brozek JL, Guyatt GH, Heels-Ansdell D, Degl’Innocenti A, Armstrong D, Fallone CA, Wiklund I, van Zanten SV, Chiba N, Barkun AN, AklEA, Schünemann HJ. Specific HRQL instruments and symptom scores were more responsive than preference-based generic instruments in patients with GERD. J Clin Epidemiol 2009; 62: 102-110.
  4. Armstrong D. A critical assessment of the current state of NERD. Digestion 2008 Vol 1 (Suppl 1); 46-54.
  5. Armstrong D. Should patients with Barrett´s esophagus be kept under surveillance? The case for. Best Pract Res Clin Gastroenterol 2008; 22: 721-739.
  6. Davids T, Sommer DD, Armstrong D. Survey of current perspectives on laryngopharyngeal reflux among Canadian otolaryngologists. J Otolaryngol (Head & Neck Surgery) 2008; 37: 196-202
  7. Armstrong D. Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther 2008; 28: 741-753.
  8. Hunt R, Armstrong D, Yaghoobi M, James C, Chen Y, Leonard J, Shin JM, Lee E, Tang-Liu D, Sachs G. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Therap 2008; 28: 187-199.
  9. Segal I, Otley A, Issenman R, Armstrong D, Espinosa V, Cawdron R, Morshed MG, Jacobson K. Prevalence of H. pylori infection in Canadian children: a cross-sectional analysis. Can J Gastroenterol 2008; 22: 485-489.
  10. Springer J, Enns R, Romagnuolo J, Ponich T, Barkun AN, Armstrong D. Canadian credentialing guidelines for endoscopic retrograde cholangiopancreatography (ERCP). Can J Gastroenterol 2008; 22: 547-551.
  11. Romagnuolo J, Enns R, Ponich T, Springer J, Armstrong D, Barkun AN. Canadian credentialing guidelines for colonoscopy. Can J Gastroenterol 2008; 22: 17-22.
  12. Tse F, Liu L, Barkun AN, Armstrong D, Moayyedi P. Endoscopic ultrasound: a meta-analysis of test performance in suspected cholelithiasis. Gastrointestinal Endoscopy 2008; 67: 235-244.
  13. Enns R, Romagnuolo J, Ponich T, Springer J, Armstrong D, Barkun AN. Canadian credentialing guidelines for flexible sigmoidoscopy. Can J Gastroenterol 2008; 22: 115-119.
  14. Armstrong D, Barkun ANG, Chen Y, Daniels S, Hollingworth R, Hunt RH, Leddin D. Access to specialist gastroenterology care in Canada: The Practice Audit in Gastroenterology (PAGE) Wait Times Program. Can J Gastroenterol 2008; 22: 155-160.
  15. Leddin D, Armstrong D, Barkun ANG, Chen Y, Daniels S, Hollingworth R, Hunt RH, Paterson WG. Access to specialist gastroenterology care in Canada: Comparison of wait times and consensus targets. Can J Gastroenterol 2008; 22: 161-167.
  16. Ponich T, Enns R, Romagnuolo J, Springer J, Armstrong D, Barkun AN. Canadian credentialing guidelines for esophagogastroduodenoscopy (EGD). Can J Gastroenterol 2008; 22: 349-354.
  17. Armstrong D, Marchetti N. Pharmacist management of GERD. Can Pharm J 2008; 15: 2008.
  18. Armstrong D, Hollingworth R. Endoscopy and quality assurance – It is here! Can J Gastroenterol 2007; 21: 255-256.
  19. Stanghellini V, Armstrong D, Monnikes H, Berghofer P, Gatz G, Bardhan KD. Determination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion 2007; 75 Suppl 1: 55-61.
  20. Bardhan KD, Stanghellini V, Armstrong D, Berghofer P, Gatz G, Monnikes H. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Digestion 2007; 75 Suppl 1: 48-54.
  21. Rabeneck L, Rumble RB, Axler J, Smith A, Armstrong D, Vinden C, Belliveau P, Rhodes K, Zwaal C, Mai V, Dixon P, Cancer Care Ontario's Colonoscopy Standards Expert Panel. Cancer Care Ontario Colonoscopy Standards: Standards and evidentiary base. Can J Gastroenterol 2007; 21 (Suppl D): 5D-24D.
  22. Armstrong D. Symptom assessment - methods and content. J Clin Gastroenterol 2007; 41: S184-192.
  23. Monnikes H, Bardhan KD, Stanghellini V, Berghofer P, Bethke TD, Armstrong D. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2007; 75 Suppl 1: 41-47.
  24. Bardhan KD, Stanghellini V, Armstrong D, Berghofer P, Gatz G, Monnikes H. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion 2007; 75 Suppl 1: 32-40
  25. Armstrong D, Mönnikes H, Bardhan KD, Stanghellini V. The construction of a new evaluative GERD questionnaire--methods and state of the art. Digestion 2007; 75 Suppl 1: 17-24.
  26. Stanghellini V, Armstrong D, Monnikes H, Bardhan KD. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Digestion 2007; 75 Suppl 1: 3-16, 2007.
  27. Armstrong D, James C, Camacho F, Chen Y, Horbay GLA, Teixeira B, Husein-Bhabha FA. Oral rabeprazole vs. intravenous pantoprazole: A comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Therap 2007; 25: 185-196.
  28. Romagnuolo J, Barkun AN, Enns R, Armstrong D, Gregor J and the RUGBE Investigator Group. Simple clinical predictors obviate urgent endoscopy in selected patients with non-variceal upper gastrointestinal bleeding. Arch Intern Med. 2007; 167: 265-270.
  29. Comay D, Blackhouse G, Goeree R, Armstrong D, Marshall JK. Photodynamic therapy for Barrett’s esophagus with high-grade dysplasia: A cost-effectiveness analysis. Can J Gastroenterol 2007; 21: 217-222.
  30. Verdu E, Mauro M, Bourgeois J, Armstrong D. Clinical onset of celiac disease after an episode of Campylobacter jejuni gastroenteritis. Can J Gastroenterol 2007; 21: 453-455.
  31. Wilkinson SB, Tarnopolsky MA, MacDonald MJ, MacDonald JR, Armstrong D, Phillips SM. Milk protein consumption promotes greater muscle protein accretion following resistance exercise than soy protein. Am J Clin Nutr 2007; 85: 1031-1040.
  32. Modlin IM, Malfertheiner P, Hunt RH, Armstrong D, Holtmann G, Quigley EM, Spechler SJ. GERD evaluation: time for a new paradigm? J Clin Gastroenterol 2007; 41: 237-41.
  33. Mauro M, Armstrong D. Juvenile onset of Crohn's disease: a risk factor for reduced lumbar bone mass in premenopausal women. Bone 2007; 40: 1290-1293.
  34. Veldhuyzen van Zanten SJO, Barkun AN, Armstrong D, White R, Junghard O, Wiklund IK. Symptom overlap in patients with upper gastrointestinal complaints in the Canadian Confirmatory Acid Suppression Test (CAST) study. Further psychometric validation of the Reflux Disease Questionnaire (RDQ). Aliment Pharmacol Therap 2007; 25: 1087-1097.
  35. Wahlqvist P, Guyatt GH, Armstrong D, Degl’ Innocenti A, Heels-Ansdell D, El-Dika S, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van Zanten SJO, Austin P, Barkun AN, Chiba N, Schünemann HJ. The Work Productivity and Activity Impairment Questionnaire for patients with Gastroesophageal Reflux Disease (WPAI-GERD): Responsiveness to change and English language validation. Pharmacoeconomics 2007; 25: 385-396.
  36. Mauro M, Armstrong D. Evaluation of densitometric bone-muscle relationships in Crohn's disease. Bone 2007; 40: 1610–1614.
  37. Moore DR, Del Bel NC, Nizi KI, Hartman JW, Tang JE, Armstrong D, Phillips SM. Resistance training reduces fasted- and fed-state leucine turnover and increases dietary nitrogen retention in previously untrained young men. J Nutr 2007; 137: 985-991.
  38. Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn’s disease patients. Can J Gastroenterol 2007; 21: 637-642.
  39. Kamath MV, Spaziani R, Ullal S, Tougas G, Guzman JC, Morillo CJ, Capogna J, Al-Bayati M, Armstrong D. The effect of sham feeding on neurocardiac regulation in healthy human volunteers. Can J Gastroenterol 2007; 21: 721-726.
  40. Armstrong D, Enns R, Ponich T, Springer J, Romagnuolo J, Barkun AN. Canadian credentialing guidelines for endoscopic privileges: an overview. Can J Gastroenterol 2007; 21: 797-801.
  41. Puhan MA, Guyatt GH, Armstrong D, Wiklund I, Fallone CA, Heels-Ansdells D, degli’Innocenti A, Veldhuyzen van Zanten SJO, Tanser L, Barkun AN, Chiba N, Austin P, El-Dika S, Schünemann HJ. Validation of a symptom diary for patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 531-541.
  42. Veldhuyzen van Zanten SJO, Chiba N, Armstrong D, Barkun AN, Thomson ABR, Mann V, Escobedo S, Chakraborty B, Nevin K. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trial. Aliment Pharmacol Ther 2006; 23: 521-529.
  43. Veldhuyzen van Zanten SJO, Thomson ABR, Barkun AN, Armstrong D, Chiba N, White RJ, Escobedo S, Sinclair P. The prevalence of Barrett’s oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy. Aliment Pharmacol Ther 2006; 23: 595-599.
  44. Cohen H, Moraes-Filho JPP, Cafferata ML, Tomasso G, Salis G, Gonzàlez O, Valenzuela J, Sharma P, Malfertheiner P, Armstrong D, Lundell L, Corti R, Sakai P, Ceconello I, and the Latin-American GORD Consensus Group. An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2006; 18: 349–368.
  45. Armstrong D, Hollingworth R, Gardiner T, Klassen M, Smith W, Hunt RH, Leddin D. Practice audit in gastroenterology (PAGE) program: qualitative study of a novel approach to continuing professional development. Can J Gastroenterol 2006; 20: 405-410.
  46. Veldhuyzen van Zanten SJO, Armstrong D, Chiba N, Flook N, White RJ, Chakraborty B, Gasco A. Esomeprazole 40 gm once-a-day in patients with functional dyspepsia: the ENTER, randomized, placebo-controlled trial. Am J Gastroenterol 2006; 101: 2096-2106.
  47. Talley NJ, Armstrong D, Junghard O, Wiklund I. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006; 24: 371-376.
  48. Mauro M, Radovic V, Zhou P, Wolfe M, Kamath M, Bercik P, Croitoru K, Armstrong D. The 13C urea breath test for Helicobacter pylori: determination of the optimal cut-off point in a Canadian community population. Can J Gastroenterol 2006; 20: 770-774.
  49. Mauro M, Radovic V, Wolfe M, Kamath M, Bercik P, Armstrong D. The 13C urea breath test: evaluation of 10-min breath collection. Can J Gastroenterol 2006; 20: 775-778.
  50. Jones R, Armstrong D, Malfertheiner P, Ducrotté P. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. Current Medical Research & Opinion 2006; 22: 657-62.
  51. Wilkinson SB, Kim PL, Armstrong D, Phillips SM. Addition of glutamine to essential amino acids and carbohydrate does not enhance anabolism in young human males following exercise. Appl Physiol Nutr Metab 2006; 31: 518-529.
  52. Sharma P, Dent J, Armstrong D, Bergman JJGHM, Gossner L, Hoshihara Y, Jankowski JA, Junghard O, Lundell L, Tytgat GNJ, Vieth M. The development and validation of an endoscopic grading system for Barrett’s esophagus – the Prague C and M criteria. Gastroenterology 2006; 131: 1392-1399.
  53. Anvari M, Allen CJ, Marshall JK, Armstrong D, Goeree R, Ungar WJ, Goldsmith CH. A randomized controlled trial of laparoscopic Nissen fundoplication (LNF) versus proton pump inhibitors for treatment of patients with chronic gastro-esophageal reflux disease (GERD): One-year follow-up. Surgical Innovation 2006; 13: 238-249.
  54. Enns RA, Gagnon YM, Barkun A, Armstrong D, Gregor J, Fedorak RN and the RUGBE Investigators. Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting. World J Gastroenterol 2006; 12: 7779-7785.
  55. Degl’Innocenti A, Guyatt GH, Wiklund I, Heels-Ansdell D, Armstrong D, Fallone CA, Tanser L, Veldhuyzen van Zanten SJO, El-Dika S, Chiba N, Barkun AN, Austin P, Schünemann HJ. The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole. Health and Quality of Life Outcomes 2005, 3:4.
  56. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, Hollingworth R, Hunt RH, Kahrilas PJ, Mayrand S, Moayyedi P, Paterson WG, Sadowski D, Veldhuyzen van Zanten SJO, for the Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults – Update 2004. Can J Gastroenterol 2005; 19: 15-35.
  57. Veldhuyzen van Zanten SJO, Chiba N, Armstrong D, Barkun AN, Thomson A, Smyth S, Escobedo S, Sinclair P. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with uninvestigated dyspepsia: the CADET-HN Study. Am J Gastroenterol 2005; 100: 1477–1488.
  58. Veldhuyzen van Zanten SJO, Bradette M, Chiba N, Armstrong D, Barkun AN, Flook N, Thomson ABR, Bursey F, for the Canadian Dyspepsia Working Group. Evidence-based recommendations for the short- and long-term management of uninvestigated dyspepsia in primary care: An update of the CanDys Clinical Management Tool. Can J Gastroenterol 2005; 19: 285-303.
  59. Armstrong D, Veldhuyzen van Zanten SJO, Chung SA, Shapiro CM, Dhillon S, Escobedo S, Chakraborty BK, Mann V, Tanser L, Nevin K. Validation of a short questionnaire in English and French for use in patients with persistent upper GI symptoms despite proton pump inhibitor (PPI) therapy: the PASS (PPI Acid Suppression Symptom) Test. Can J Gastroenterol 2005; 19: 350-358.
  60. Armstrong D, Veldhuyzen van Zanten SJO, Barkun AN, Chiba N, Thomson ABR, Smyth S, Sinclair P, Chakraborty B and the CADET-HR Study Group. Heartburn-Dominant, Uninvestigated Dyspepsia: A Comparison of 'PPI-Start' and 'H2-RA-Start' Management Strategies in Primary Care - the CADET-HR Study. Aliment Pharmacol Ther 2005; 21: 1189-1202.
  61. Marshall JK, Gadowsky SL, Childs A, Armstrong D. Economic analysis of home versus hospital-based parenteral nutrition in Ontario, Canada. JPEN J Parent Ent Nutr 2005; 29: 266-269.
  62. Stanghellini V, Armstrong D, Mönnikes H, Berghöfer P, Gatz G, Bardhan KD. Determination of ReQuest™-based symptom thresholds to define symptom relief in GERD clinical studies. Digestion 2005; 71: 145–151.
  63. Bercik P, Schlageter V, Mauro M, Kucera P, Rawlinson J, Armstrong D. Non-invasive verification of nasogastric tube placement using a magnet-tracking system: a pilot study in healthy subjects. JPEN: J Parent Ent Nutr 2005; 29: 305-310.
  64. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Nauclér E, Eklund S. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive esophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739–746.
  65. El-Dika S, Guyatt GH, Armstrong D, Degl'Innocenti A, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van Zanten SJO, Heels-Ansdell D, Wahlqvist P, Chiba N, Barkun AN, Austin P, Schünemann HJ. The impact of illness in patients with moderate to severe gastroesophageal reflux disease. BMC Gastroenterology 2005; 5:23 (doi:10.1186/1471-230X-5-23)
  66. Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, Taccoen A, Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005; 100: 1949-1956.
  67. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Naucler E, Adler J, Eklund S. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22: 803-11
  68. Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord 2005;5(Suppl 2):S18-S30.
  69. Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004; 53 (Suppl 4): iv1-iv24.
  70. Chan R, Armstrong D. Peripheral intravenous infusion of potassium chloride: effect of solution composition on infusion-site pain. Can J Hosp Pharm 2004; 57: 27-31.
  71. Liu LWC, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol 2004; 18: 397-399.
  72. Schünemann HJ, Stahl E, Austin P. Akl E, Armstrong D, Guyatt GH. A comparison of narrative and table formats for presenting hypothetical health states to patients with gastrointestinal or pulmonary disease. Medical Decision Making 2004; 24: 53-60.
  73. Chiba N, Veldhuyzen van Zanten SJO, Escobedo S, Grace E, Lee J, Sinclair P, Barkun A, Armstrong D, Thomson AB. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther 2004; 19: 349-358.
  74. Stanghellini V, Armstrong D, Mönnikes H, Bardhan KD. Do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19: 463-480.
  75. Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, Rahme E, Toubouti Y, Martel M, Chiba N, Fallone CA and the RUGBE Investigators. The Canadian registry on non-variceal upper gastrointestinal bleeding and endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real life setting. Am J Gastroenterol 2004; 99: 1238-46.
  76. Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, Venables T, Green J, Bigard MA, Mossner J, Junghard O. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20: 413–421.
  77. Armstrong D. Gastric pH – the most relevant predictor of benefit in reflux disease. Aliment Pharmacol Ther 2004; 20(Suppl 5) 19-26.
  78. Armstrong D. Towards consistency in the endoscopic diagnosis of Barrett’s oesophagus and columnar metaplasia. Aliment Pharmacol Ther 2004; 20 (Suppl 5) 40-47.
  79. Phillips SM, Stewart BG, Mahoney DJ, Hicks AL, McCartney N, Tang JE, Wilkinson SB, Armstrong D, Tarnopolsky MA.  Body-weight-support treadmill training improves blood glucose regulation in persons with incomplete spinal cord injury. J Appl Physiol 2004; 97: 716-724.
  80. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H. Evaluation of GERD symptoms during therapy Part 1: Development of the new GERD questionnaire ReQuest. Digestion 2004; 69: 229-237.
  81. Mönnikes H, Bardhan KD, Stanghellini V, Berghöfer P, Bethke TD, Armstrong D. Evaluation of GERD symptoms during therapy Part II: psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69: 238-244.
  82. Armstrong D, Mönnikes H, Bardhan KD, Stanghellini V. The construction of a new evaluative GERD questionnaire – methods and state of the art. Digestion 2004; 70: 71-78.
  83. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P. Gatz G, Mönnikes H. International validation of ReQuest in patients with endoscopy negative gastroesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 891-898.
  84. Armstrong D. Does H. pylori infection and eradication have any effect on heartburn and gastroesophageal reflux? Nature Clinical Practice: Gastroenterology and Hepatology 2004; 1: 16-17. (doi: 10.1038/ncpgasthep0004)
  85. Fallone CA, Guyatt GH, Armstrong D, Wiklund I, Degl’Innocenti A, Heels-Ansdell, D, Barkun AN, Chiba N, Veldhuyzen van Zanten SJO, El-Dika, S, Austin P, Tanser L, Schünemann HJ. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004; 20:1161-1169.
  86. Schünemann HJ, Armstrong D, Degl’innocenti A, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van Zanten SJO, Heels-Ansdell, D, El-Dika S, Chiba N, Barkun AN, Austin P, Guyatt G. A randomized multicentre trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Medical Care 2004; 42: 1132-42.

Dr. Premsyl Bercik

  1. Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA, Lu J, Khan W, Corthesy-Theulaz I, Cherbut C, Bergonzelli GE, Collins SM. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology. 2010 Jul 2. [Epub ahead of print] PubMed PMID: 20600016.
  2. Xenodemetropoulos T, Khan KJ, Bercik P. Spontaneous intramural esophageal hematoma in association with idiopathic thrombocytopenic purpura: a cause of non-cardiac chest pain. Clin Gastroenterol Hepatol. 2010 Jul; 8: e73-4.
  3. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis. 2009; 41: 850-3.
  4. Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MA, Geuking MB, Beutler B, Tedder TF, Hardt WD, Bercik P, Verdu EF, McCoy KD, Macpherson AJ. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science. 2009; 325: 617-20.
  5. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009; 136: 2003-14.
  6. Bercik P, Verdu EF, Foster JA, Lu J, Scharringa A, Kean I, Wang L, Blennerhassett P, Collins SM. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. Am J Physiol Regul Integr Comp Physiol. 2009; 296: R587-94.
  7. Bercik P, Verdú EF, Foster JA, Lu J, Scharringa A, Kean I, Wang L,Blennerhassett P, Collins SM. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. Am J Physiol Regul Integr Comp Physiol. 2009 Mar; 296: R587-94
  8. Collins S, Verdu E, Denou E, Bercik P. The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome. Dig Dis. 2009; 27 Suppl 1:85-9.
  9. Verdu EF, Bercik P, Huang XX, Lu J, Al-Mutawaly N, Sakai H, Tompkins TA,Croitoru K, Tsuchida E, Perdue M, Collins SM. The role of luminal factors in the recovery of gastric function and behavioral changes after chronic Helicobacter pylori infection. Am J Physiol Gastrointest Liver Physiol. 2008 Oct; 295: G664-70.
  10. Verdu EF, Bercik P, Huang XX, Lu J, Al-Mutawaly N, Sakai H, Tompkins TA,Croitoru K, Tsuchida E, Perdue M, Collins SM. The role of luminal factors in the recovery of gastric function and behavioral changes after chronic Helicobacter pylori infection. Am J Physiol Gastrointest Liver Physiol. 2008 Oct; 295: G664-70.
  11. Verma-Gandhu M, Verdu EF, Bercik P, Blennerhassett PA, Al-Mutawaly N, Ghia JE, Collins SM. Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse. Gut 2007; 56: 358-64.
  12. Verdu EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182-90.
  13. Verma-Gandhu M, Bercik P, Motomura Y, Verdu EF, Khan WI, Blennerhassett PA, Wang L, El-Sharkawy RT, Collins SM. CD4+ T-cell modulation of visceral nociception in mice. Gastroenterology 2006; 130: 1721-8.
  14. Varghese AK, Verdú EF, Bercik P, Khan WI, Blennerhassett PA, Szechtman H, Collins SM. Antidepressants attenuate increased susceptibility to colitis in a murine model of depression. Gastroenterology 2006; 130: 1743-53.
  15. Mauro M, Radovic V, Zhou P, Wolfe M, Kamath M, Bercik P, Croitoru K, Armstrong D. 13C urea breath test for Helicobacter pylori: Determination of the optimal cut-off point in a Canadian community population. Can J Gastroenterol. 2006; 20: 770-4.
  16. Mauro M, Radovic V, Wolfe M, Kamath M, Bercik P, Armstrong D. 13C urea breath test for Helicobacter pylori: Evaluation of 10-minute breath collection. Can J Gastroenterol.2006; 20: 775-8.
  17. Vallance BA, Gunawan MI, Hewlett B, Bercik P, Van Kampen C, Galeazzi F, Sime PJ, Gauldie J, Collins SM. TGF-ß 1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol. 2005; 289: G116-28.
  18. Wang XY, Lammers WJ, Bercik P, Huizinga JD. Lack of pyloric interstitial cells of Cajal explains distinct peristaltic motor patterns in stomach and small intestine. Am J Physiol Gastrointest Liver Physiol. 2005; 289: G539-49.
  19. Bercik P, Schlageter V, Mauro M, Rawlinson J, Kucera P, Armstrong D. Non-invasive verification of nasogastric tube placement using a magnet tracking system: A pilot study in healthy subjects. JPEN 2005; 29: 305-10.
  20. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am. 2005; 34: 235-45.
  21. Bercik P, Wang L, Verdú EF, Mao YK, Blennerhassett P, Khan WI, Kean I, Tougas G, Collins SM. Visceral hyperalgesia and intestinal dysmotility in a mouse model of post-infective gut dysfunction. Gastroenterology 2004; 127: 179-87.
  22. Verdú EF, Bercik P, Blennerhasset P, Huang XX, Bergonzelli G, Rochat F, Corthésy-Theulaz I and Collins SM. Lactobacillus paracasei normalizes muscle hyper-contractility in a murine model of post-infective gut dysfunction. Gastroenterology2004; 127: 826-37.

Professor Stephen Collins

  1. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM; Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010; 59: 605-11.
  2. Thabane M, Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Collins SM, Salvadori M, Marshall JK. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010; 105: 933-9.
  3. Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology. 2010; 138: 1727-36.
  4. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010; 138: 1502-13.
  5. Bercik P, Verdu EF, Foster JA, Macri J, Potter M, Huang X, Malinowski P, Jackson W, Blennerhassett P, Neufeld KA, Lu J, Khan W, Corthesy-Theulaz I, Cherbut C, Bergonzelli GE, Collins SM. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology. 2010 . [Epub ahead of print] PubMed PMID: 20600016.
  6. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis. 2009; 41: 850-3.
  7. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology. 2009; 136: 2003-14.
  8. Bercik P, Verdu EF, Foster JA, Lu J, Scharringa A, Kean I, Wang L, Blennerhassett P, Collins SM. Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. Am J Physiol Regul Integr Comp Physiol. 2009; 296: R587-94.
  9. Collins S, Verdu E, Denou E, Bercik P. The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome. Dig Dis. 2009; 27 Suppl 1:85-9.
  10. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 2009; 136: 2280-2288
  11. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM. Reactivation of Inflammatory Bowel Disease in a Mouse Model of Depression. Gastroenterology. 2009 Mar 9. [Epub ahead of print] PubMed PMID: 19272381.
  12. Bercik P, Verdú EF, Foster JA, Lu J, Scharringa A, Kean I, Wang L,   Blennerhassett P, Collins SM. Role of gut-brain axis in persistent abnormalfeeding behavior in mice following eradication of Helicobacter pylori infection. Am J Physiol Regul Integr Comp Physiol. 2009 ; 296: R587-94.
  13. Zhu Q, Thomson CW, Rosenthal KL, McDermott MR, Collins SM, Gauldie J.Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. MucosalImmunol. 2008; 1: 78-88. PubMed PMID: 19079163.
  14. Verdu EF, Bercik P, Huang XX, Lu J, Al-Mutawaly N, Sakai H, Tompkins TA,Croitoru K, Tsuchida E, Perdue M, Collins SM. The role of luminal factors in the recovery of gastric function and behavioral changes after chronic Helicobacter pylori infection. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G664-70.
  15. Ghia JE, Blennerhassett P, Collins SM. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J Clin Invest. 2008; 118: 2209-18.
  16. Spaziani R, Bayati A, Redmond K, Bajaj H, Mazzadi S, Bienenstock J, Collins SM, Kamath MV. Vagal dysfunction in irritable bowel syndrome assessed by rectal distension and baroreceptor sensitivity. Neurogastroenterol Motil. 2008; 20: 336-42.
  17. Collins SM. The relationship of enteric microbial infection and functional bowel disorders. J Clin Gastroenterol. 2007; 41 Suppl 1: S30-2.
  18. Paré P, Bridges R, Champion M, Ganguli S, Gray JR, Irvine EJ, Plourde V, Poitras P, Turnbull GK, Moayyedi P, Flook N and Collins SM. Recommendations on Chronic Constipation (including constipation associated with IBS) Treatment. Can J Gastroenterology. Can J Gastroenterol. 2007 Apr; 21 Suppl B:3B-22.
  19.  Akiho H, Khan WI, Al-Kaabi A, Blennerhassett P, Deng Y, Collins SM. Cytokine modulation of muscarinic receptors in the murine intestine. Am J Physiol Gastrointest Liver Physiol. 2007 Apr 12;
  20. Zhu Q, Thomson CW, Zhang G, Stampfli M, McDermott MR, Collins SM, Gauldie J. Eosinophilia is induced in the colon of Th-2 sensitized mice upon exposure to locally expressed antigen. Am J Physiol Gastrointest Liver Physiol. 2007 Apr 12.
  21. Vallance BA, Radojevic N, Hogaboam CM, Deng Y, Gauldie J, Collins SM.  IL-4 gene transfer to the small bowel serosa leads to intestinal inflammation and smooth muscle hyperresponsiveness. Am J Physiol Gastrointest Liver Physiol. 2007 Jan; 292: G385-94
  22. Piche T, Vanbiervliet G, Pipau FG, Dainese R, Hébuterne X, Rampal P, Collins SM. Low risk of irritable bowel syndrome after Clostridium difficile infection.Can J Gastroenterol. 2007; 21: 727-31.
  23. Collins SM. Translating symptoms into mechanisms: functional GI disorders. Adv Physiol Educ. 2007; 31: 329-31.
  24. Korolchuk VI, Schütz MM, Gómez-Llorente C, Rocha J, Lansu NR, Collins SM, Wairkar YP, Robinson IM, O'Kane CJ. Drosophila Vps35 function is necessary for normal endocytic trafficking and actin cytoskeleton organisation. J Cell Sci. 2007 15; 120: 4367-76.
  25. Ghia JE, Blennerhassett P, El-Sharkawy RT, Collins SM. The protective effect of the vagus nerve in a murine model of chronic relapsing colitis. Am J Physiol Gastrointest Liver Physiol. 2007; 293: G711-8.
  26. Ganguli SC, Kamath MV, Redmond K, Chen Y, Irvine EJ, Collins SM, Tougas G. A comparison of autonomic function in patients with inflammatory bowel disease and in healthy controls. Neurogastroenterol Motil. 2007; 19: 961-7.
  27. Motomura Y, Khan WI, El-Sharkawy RT, Verma-Gandhu M, Verdu EF, Gauldie J, Collins SM.  Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1. Gut. 2006; 55: 662-70. Epub 2005 Nov 18.
  28. Verdu EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM.  Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice.Gut. 2006; 55: 182-90. Epub 2005 Aug 16. PMID: 6105890 [PubMed - indexed for MEDLINE
  29. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM; Walkerton Health    Study Investigators.  Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006; 131: 445-50; quiz 660. PMID: 16890598
  30. Borgaonkar MR, Ford DC, Marshall JK, Churchill E, Collins SM. The incidence of irritable bowel syndrome among community subjects    with previous acute enteric infection Dig Dis Sci. 2006; 51: 1026-32. Epub 2006. PMID: 16758307.
  31. Khan WI, Motomura Y, Wang H, El-Sharkawy RT, Verdu EF, Verma-Gandhu M, Rollins BJ, Collins SM. Critical Role of MCP-1 in the Pathogenesis of Experimental Colitis in the Context of Immune and Enterochromaffin Cells. Am J Physiol Gastrointest Liver Physiol. 2006; 291: G803-11.
  32. Varghese AK, Verdu EF, Bercik P, Khan WI, Blennerhassett PA, Szechtman H, Collins SM.  Antidepressants attenuate increased susceptibility to colitis in a murine model of depression.Gastroenterology. 2006; 130: 1743-53.
  33. Verma-Gandhu M, Bercik P, Motomura Y, Verdu EF, Khan WI, Blennerhassett PA, Wang L, El-Sharkawy RT, Collins SM.  CD4+ T-cell modulation of visceral nociception in mice. Gastroenterology. 2006; 130: 1721-8.
  34. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Tache Y, Wood JD.  Fundamentals of neurogastroenterology: basic science.Gastroenterology. 2006 ; 130: 1391-411.
  35. Khan WI, Collins SM.  Gut motor function: immunological control in enteric infection and inflammation. Clin Exp Immunol. 2006 ; 143: 389-97.
  36. Collins SM, Verma-Gandhu M.  The putative role of endogenous and exogenous opiates in inflammatory bowel disease.  Gut 2006 ; 55: 756-7.  PMID:  16698748 [PubMed – indexed for MEDLINE].
  37. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM.  The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology. 2006; 131: 1122-30. Epub 2006 Aug 15.
  38. Verma-Gandhu M, Verdu EF, Bercik P, Blennerhassett PA, Al-Mutawaly N, Ghia JE, Collins SM. Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse. Gut. 2006;
  39. Verma-Gandhu M, Verdu EF, Cohen-Lyons DP, Collins SM.  Lymphocyte mediated regulation of {beta}-endorphin in the myenteric plexus. Am J Physiol Gastrointest Liver Physiol. 2006 Sep 7; [Epub ahead of print] PMID: 16959949 [PubMed - as supplied by publisher].
  40. Martin FP, Verdu EF, Wang Y, Dumas ME, Yap IK, Cloarec O, Bergonzelli GE, Corthesy-Theulaz I, Kochhar S, Holmes E, Lindon JC, Collins SM, Nicholson JK. Transgenomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation.J Proteome Res. 2006; 5: 2185-93.
  41. Vallance BA, Gunawan MI, Hewlett B, Bercik P, VanKampen C, Galeazzi F, Sime PJ, Gauldie J &  Collins SM.  TGF1 gene transfer to the mouse colon leads to intestinal fibrosis and stricture formation. AJP – GI and Liver Physiology.  G-10051, February, 2005.
  42. Akiho H, Deng Y, Blennerhassett P, Kanbayashi H, Collins SM. Mechanisms underlying the maintenance of muscle hypercontractility  in a model of postinfective gut dysfunction. .Gastroenterology. 2005 ; 129: 131-41.
  43. Collins SM.   Dysregulation of peripheral cytokine production in irritable bowel syndrome. Am J Gastroenterol. 2005; 100: 2517-8. PMID: 16279908 [PubMed - indexed for MEDLINE]
  44. Akiho H, Lovato P, Deng Y, Ceponis PJ, Blennerhassett P, Collins SM.  Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease.Am J Physiol Gastrointest Liver Physiol. 2005; 288: G609-15.
  45. Khan WI, Motomura Y, Blennerhassett PA, Kanbayashi H, Varghese AK, El-Sharkawy RT, Gauldie J, Collins SM.  Disruption of CD40-CD40 ligand pathway inhibits the development of intestinal muscle hypercontractility and protective immunity in nematode infection. Am J Physiol Gastrointest Liver Physiol. 2005; 288: G15-22.
  46. Motomura Y, Kanbayashi H, Khan WI, Deng Y, Blennerhassett PA, Margetts PJ,Gauldie J, Egashira K, Collins SM.  The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.Am J Physiol Gastrointest Liver Physiol. 2005; 288: G143-50. Epub 2004 Aug.
  47. Motomura Y, Kanbayashi H, Khan WI, Deng Y, Blennerhassett PA, Margetts PJ, Gauldie J, Egashira K, Collins SM. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-{beta} type II receptor gene transfer.Am J Physiol Gastrointest Liver Physiol. 2005 Jan; 288: G143-G150.
  48. VanKampen C, Gauldie J &  Collins SM.  The proinflammatory properties of interleuken-4 (IL-4) in the intestinal microenvironment.  Amer. Phy. Soc.;  2004 288: 111-117.
  49. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Santini D, Pasquinelli G, Morselli-Labate, Cottrell G, Grady E, Bunnett N, Collins SM and R. Corinaldesi. Activated mast cells release tryptase and histamine in proximity to colonic nerves in irritable bowel syndrome. MS# 02-0838-00.  Gastroenterology, 2004 March; 126: 693-702..
  50. Verdu EF, Collins SM.  Microbial-gut interactions in health and disease.  Irritable bowel syndrome.  Best Pract. Res. Clin. Gastroenterol. 2004 April; 18: 315-21.
  51. Collins SM.  Putative therapeutic targets in the treatment of visceral hyperalgesia.  GUT, 2004 March; Vol 53, Supp II: 19-21.
  52. Collins SM, Barbara, G.  East meets West: infection, nerves and mast cells in the irritable bowel syndrome.  Gut  2004; 53: 10068-10069.
  53. Vallance, BA, Dijkstra G, Qiu BS, van der Waaij LA, van Goor H, Jansen PLM, Mashimo H and Collins SM. Relative contributions of nitric oxide synthase (NOS) isoforms during experimental colitis: endothelial derived NOS maintains mucosal integrity. AJP, Gastrointest. Liver Physiol.  October 2004. 187: G865-74.
  54. Verdu EF, Bercik P, Bergonzelli GE, Huang XX, Blennerhasset P, Rochat F, Fiaux M, Mansourian R, Corthesy-Theulaz I, Collins SM. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction.Gastroenterology. 2004; 7: 826-37.
  55. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM, Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario.Aliment Pharmacol Ther. 2004; 20: 1317-22.
  56. Bercik P, Wang L, Verdu EF, Mao YK, Blennerhassett P, Khan WI, Kean I, Tougas G, Collins SM. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004 ; 127: 179-87.
  57. Mawe GM, Collins SM, Shea-Donohue T. Changes in enteric neural circuitry and smooth muscle in the inflamed and infected gut. Neurogastroenterol Motil. 2004; 16 Suppl 1: 133-6.
  58. Khan WI, Collins SM.  Immune-mediated alteration in gut physiology and its role in host defence in nematode infection. Parasite Immunol. 2004; 26: 319-26.

Dr. Subash Ganguli

  1. SC Ganguli , MV Kamath , K Redmond, Y Chen , EJ Irvine , SM Collins and G Tougas. A Comparison of Autonomic Function in Patients with Inflammatory Bowel Disease and in Healthy Controls. Neurogastroenterology and Motility 2007;19:961-967
  2. Pare P, Bridges R, Champion MC, Ganguli SC, Gray JR, Irvine EJ, Plourde V, Poitras P, Turnbull GK, Moayyedi P, Flook N, Collins SM. Recommendations on chronic constipation (including constipation with irritable bowel syndrome) treatment. Can J Gastroenterol 2007 Apr; 21 Suppl B:3B-22B
  3. SC Ganguli, R Cawdron, EJ Irvine. Alternative Medicine Use by Canadian Ambulatory Gastroenterology Patients: Secular Trend or Epidemic? American Journal of Gastroenterology 2004;99: 319-326

Dr. Eric Greenwald

  1. Greenwald E, Rawlinson J, Marshall JK. A distinctive case of dysphagia. Can Med Assoc J 2004;170:42.

Dr. Smita Halder

  1. Chang JY, Locke GR 3rd, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, Talley NJ. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010; 105: 822-32
  2. Kabakchiev B, Halder SLS, Silverberg MS. Molecular Tests for Differential Diagnosis in Inflammatory Bowel Disease. Molecular Diagnosis & Therapy2009;13: 217-23
  3. Nicholl BI, Halder SLS, Macfarlane GJ, Thompson DG, O'Brien SJ, Musleh M, McBeth J. Psychosocial risk markers for new onset irritable bowel syndrome - Results of a large prospective population-based study. Pain 2008; 137: 147-55.
  4. O’Brien S, Halder SLS. GI Epidemiology: infection epidemiology and acute gastrointestinal infections. Alimentary Pharmacology & Therapeutics 2007; 25: 669-674.
  5. Halder SLS, Locke GR, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Natural history of functional gastrointestinal disorders: a 15-year longitudinal population-based study. Gastroenterology 2007; 133: 799-807.
  6. Jung HK, Halder S, McNally MA, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Overlap of gastroesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Alimentary Pharmacology & Therapeutics 2007; 26: 453-61.
  7. Halder SL, Talley NJ. Functional dyspepsia: A new Rome III paradigm. Current Treatment Options Gastroenterol. 2007; 10: 259-72.
  8. El-Metwally A, Halder SL, Thompson DG, Macfarlane GJ, Jones GT. Predictors of abdominal pain in schoolchildren: A 4-year population-based prospective study. Arch Dis Child 2007; 92: 1094-8.
  9. Halder SLS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Influence of alcohol consumption on IBS and dyspepsia. Neurogastroenterology & Motility 2006; 18: 1001-1008.
  10. Halder SLS, Talley NJ. Treatment of functional dyspepsia. Current Treatment Options Gastroenterol.  2005; 8: 325-36.
  11. Halder SLS, Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Alimentary Pharmacology & Therapeutics 2004; 19: 233-42.

Professor Richard Hunt

  1. Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010; 105: 1007-13.
  2. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010; 152: 101-13.
  3. Yaghoobi M, Padol S, Yuan Y, Hunt RH. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis. Eur J Gastroenterol Hepatol. 2010; 22: 583-90.
  4. Hunt RH, Armstrong D, Yaghoobi M, James C. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther. 2010; 31: 648-57.
  5. Padol IT, Hunt RH. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology 2010; 49: 837-43.
  6. Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GN, Tack J, Heading RC, Holtman G, Moss SF; Vevey NERD Consensus Group. Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion. 2009; 80: 74-88.
  7. Yuan YH, Wang C, Yuan Y, Hunt RH. Meta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials. Aliment Pharmacol Ther. 2009; 30: 197-209.
  8. Hunt RH, Lanas A, Stichtenoth DO, Scarpignato C. Myths and facts in the use of anti-inflammatory drugs. Ann Med. 2009; 8: 1-16.
  9. Yuan Y, Hunt RH. Evolving issues in the management of reflux disease? Curr
    Opin Gastroenterol. 2009; 25: 342-51.
    10. Yuan Y, Hunt RH. Systematic reviews: the good, the bad, and the ugly. Am J Gastroenterol. 2009 May;104(5):1086-92.
  10. Yuan Y, Hunt RH. Systematic reviews: the good, the bad, and the ugly. Am J Gastroenterol. 2009 May; 104: 1086-92.
  11. Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol. 2009 Feb;104(2):492-500
  12. Yuan Y, Hunt RH. A balancing view: Evidence-based medicine: neither savior nor scourge but a practical tool for clinical practice. Am J Gastroenterol. 2008 Dec;103(12):2969-71.
  13. Wang C, Hunt RH. Medical management of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2008 Dec;37(4):879-99
  14. Wang C, Hunt RH. Precise role of acid in non-erosive reflux disease. Digestion. 2008;78 Suppl 1:31-41.
  15. Modlin IM, Hunt RH, Malfertheiner P, Moayyedi P, Quigley EM, Tytgat GN, Tack J, Holtmann G, Moss SF. Non-erosive reflux disease--defining the entity and delineating the management. Digestion. 2008;78 Suppl 1:1-5.
  16. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning?. Curr Opin Pharmacol. 2008 Dec;8(6):677-84.
  17. Yuan Y, Wang C, Hunt RH. Endoscopic clipping for acute nonvariceal upper-GI bleeding: a meta-analysis and critical appraisal of randomized controlled trials. Gastrointest Endosc. 2008 Aug;68(2):339-51.
  18. Hunt RH, Armstrong D, Yaghoobi M, James C, Chen Y, Leonard J, Shin JM, Lee E, Tang-Liu D, Sachs G. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther. 2008 Jul;28(2):187-99.
  19. Leddin D, Armstrong D, Barkun AN, Chen Y, Daniels S, Hollingworth R, Hunt RH, Paterson WG. Access to specialist gastroenterology care in Canada: comparison of wait times and consensus targets. Can J Gastroenterol. 2008 Feb;22(2):161-7.
  20. Armstrong D, Barkun AN, Chen Y, Daniels S, Hollingworth R, Hunt RH, Leddin D. Access to specialist gastroenterology care in Canada: the Practice Audit in Gastroenterology (PAGE) Wait Times Program. Can J Gastroenterol. 2008 Feb;22(2):155-60.
  21. Fried M, Quigley EM, Hunt RH, Guyatt G, Anderson BO, Bjorkman DJ, Farthing MJ, Fedail SS, Green-Thompson R, Hampton J, Krabshuis J, Laine L, Horton R. Are global guidelines desirable, feasible and necessary?. Nat Clin Pract Gastroenterol Hepatol. 2008 Jan;5(1):2-3.
  22. Fried M, Quigley EM, Hunt RH, Guyatt G, Anderson BO, Bjorkman DJ, Farthing MJ, Fedail SS, Green-Thompson R, Hampton J, Krabshuis J, Laine L, Horton R. Is an evidence-based approach to creating guidelines always the right one?. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb;5(2):60-1.
  23. Fried M, Quigley EM, Hunt RH, Guyatt G, Anderson BO, Bjorkman DJ, Farthing MJ, Fedail SS, Green-Thompson R, Hampton J, Krabshuis J, Laine L, Horton R. Can global guidelines change health policy?. Nat Clin Pract Gastroenterol Hepatol. 2008 Mar;5(3):120-1.
  24. Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, Hungin AP, Batchelor HK. New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008 Feb 1;27(3):249-56.
  25. Hunt RH, Choquette D, Craig BN, De Angelis C, Habal F, Fulthorpe G, Stewart JI, Turpie AG, Davis P. Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. Can Fam Physician. 2007 Jul;53(7):1177-84. Review. PubMed PMID: 17872814; PubMed Central PMCID: PMC1949301.
  26. Yuan Y, Hunt RH. Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des. 2007;13(22):2237-47.
  27. Hunt RH, Tytgat GH, Malfertheiner P, Fock KM, Heading RC, Katelaris PH, McCarthy DM, McColl KE, Moss SF, Sachs G, Sontag SJ, Thomson AB, Modlin IM. Whistler summary: "the slow rate of rapid progress". J Clin Gastroenterol. 2007 Jul;41(6):539-45.
  28. Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol. 2007 Aug;102(8):1789-98.
  29. Modlin IM, Malfertheiner P, Hunt RH, Armstrong D, Holtmann G, Quigley EM, Spechler SJ. GERD evaluation: time for a new paradigm?. J Clin Gastroenterol. 2007 Mar;41(3):237-41.
  30. Hunt RH, Dhaliwal S, Tougas G, Pedro C, Labbé JF, Paul H, Ennamorato M. Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: A descriptive study. Can J Gastroenterol. 2007 Jan;21(1):31-7.
  31. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?. Am J Med. 2006 Sep;119(9):719- 27.
  32. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006 Jul;101(7):1467-75.
  33. Armstrong D, Hollingworth R, Gardiner T, Klassen M, Smith W, Hunt RH, Barkun A, Gould M, Leddin D. Practice Audit in Gastroenterology (PAGE) program: a novel approach to continuing professional development. Can J Gastroenterol. 2006 Jun;20(6):405-10.
  34. Yuan Y, Thabane L, Hunt RH. Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence?. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1283-5.
  35. Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb;3(2):80-9.
  36. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005 Dec;22 Suppl 3:10-9.
  37. Bowen B, Yuan Y, James C, Rashid F, Hunt RH. Time course and pattern of blood loss with ibuprofen treatment in healthy subjects. Clin Gastroenterol Hepatol. 2005 Nov;3(11):1075-82.
  38. Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, Taccoen A, Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005 Sep;100(9):1949-56.
  39. Huang JQ, Zheng GF, Hunt RH, Wong WM, Lam SK, Karlberg J, Wong BC. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol. 2005 May 14;11(18):2726-32.
  40. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, Hollingworth R, Hunt RH, Kahrilas PJ, Mayrand S, Moayyedi P, Paterson WG, Sadowski D, van Zanten SJ; Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005 Jan;19(1):15-35.
  41. Padol IT, Hunt RH. Host-specific differences in the physiology of acid secretion related to prostaglandins may play a role in gastric inflammation and injury. Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1110-7.
  42. Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1161-6.
  43. Hunt RH. Will eradication of Helicobacter pylori infection influence the risk of gastric cancer?. Am J Med. 2004 Sep 6;117 Suppl 5A:86S-91S.
  44. Sagar M, Padol I, Khan WI, Bonin RP, Blennerhassett PA, Hunt RH. Establishment of T-Helper-2 immune response based gerbil model of enteric infection. Scand J Gastroenterol. 2004 Jul;39(7):668-73.
  45. Moayyedi P, Hunt RH. Helicobacter pylori public health implications. Helicobacter. 2004;9 Suppl 1:67-72.
  46. Padol IT, Hunt RH. Effect of Th1 cytokines on acid secretion in pharmacologically characterised mouse gastric glands. Gut. 2004 Aug;53(8):1075-81.
  47. Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:9-16.

Dr. Khurram Khan

  1. Xenodemetropoulos T, Khan KJ, Bercik P. Spontaneous intramural esophageal hematoma in association with idiopathic thrombocytopenic purpura: a cause of non-cardiac chest pain. Clin Gastroenterol Hepatol. 2010 Jul;8(7):e73-4. Epub 2010 Mar 3. PubMed PMID: 20206295.
  2. Khan KJ. Prevalence, diagnosis, and profile of autoimmune pancreatitis presenting with features of acute or chronic pancreatitis. Clin Gastroenterol Hepatol. 2010; 8: 639-40.

Dr. Grigoris Leontiadis

  1. Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010; 7:CD005415.
  2. Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol. 2010; 105: 1240-8.
  3. Leontiadis GI, Tse F, Howden CW. Antiplatelet therapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. Key messages for clinical practice. Pol Arch Med Wewn. 2010; 120: 143-7.
  4. Leontiadis GI, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal bleeding. Gastroenterol Clin North Am. 2009; 38: 199-213.
  5. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;  11: 1-164
  6. Koulaouzidis A, Leontiadis GI, Said E, Saeed AA. Bedside leucocyte esterase reagent strips in spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol2007; 19: 913
  7. Leontiadis GI, Maltezos E, Howden CW. Should we give a PPI i.v. before endoscopy in patients with upper GI bleeding? Pol Arch Med Wewn 2007; 117: 210-2
  8. Howden CW, Leontiadis GI. Early infusion of high-dose omeprazole before endoscopy reduced the need for endoscopic therapy. ACP J Club 2007; 147: 18
  9. Leontiadis GI, Howden CW. Pharmacologic Treatment of Peptic Ulcer Bleeding. Curr Treat Options Gastroenterol 2007; 10: 134-142
  10. Moschos J, Kouklakis G, Leontiadis G, Koulaouzidis A, Kadis S, Mpoumponaris A, Molyvas E, Minopoulos G. 3-hour postprandial pH monitoring study correlation with endoscopy in gastroesophageal reflux disease. J Coll Physicians Surg Pak 2007; 17: 180-1
  11. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 286-96
  12. Dorward S, Sreedharan A, Leontiadis GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2006 18; CD005415
  13. Leontiadis GI, Sharma VK, Howden CW.  Proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol 2006; 21: 1763-5
  14. Leontiadis GI, Howden CW. To establish the efficacy of PPI therapy for ulcer bleeding in the United States, do we need more patients or more PPI. Am J Gastroenterol 2006; 101: 2000-2
  15. Triester SL, Leighton JA, Leontiadis GI, Gurudu SR, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn's disease. Am J Gastroenterol 2006; 101: 954-64.
  16. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006  25; D002094
  17. Kouklakis G, Moschos J, Leontiadis GI, Kadis S, Mpoumponaris A, Molyvas E, Minopoulos GI. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol 2005; 14: 401-3
  18. Leontiadis GI, Sharma VK, Howden CW. Explaining divergent results of meta-analyses on proton pump inhibitor treatment for ulcer bleeding. Gastroenterology2005; 129: 1804-5
  19. Triester SL, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. Am J Gastroenterol 2005 ; 100: 2407-18
  20. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion
  21.  requirements and hospital stay--results from the Cochrane Collaboration. Aliment Pharmacol Ther 2005; 22: 169-74
  22. Leontiadis GI, Moschos J, Cowper T, Kadis S. Mortality of percutaneous endoscopic gastrostomy in the UK. J Postgrad Med 2005; 51: 152
  23. Moschos J, Leontiadis GI, Kelly C, Henry J, Kadis S. Idiopathic portal hypertension complicating systemic sclerosis: a case report. BMC Gastroenterol2005; 5: 16
  24. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia - a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005; 21: 1055-61
  25. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568
  26. Leontiadis GI, Howden CW. Who's afraid of the big bad GERD? J Clin Gastroenterol 2004; 38: 731-2
  27. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004; (3):CD002094
  28. Leontiadis GI, Minopoulos GI, Maltezos E, Kotsiou S, Manolas KI, Simopoulos K, Hatseras D. Effects of Helicobacter pylori infection on gastric emptying rate in patients with non-ulcer dyspepsia. World J Gastroenterol 2004; 10: 1750-4

Professor Andrew Macpherson

  1. Hapfelmeier S, Lawson MA, Slack E, Kirundi JK, Stoel M, Heikenwalder M, Cahenzli J, Velykoredko Y, Balmer ML, Endt K, Geuking MB, Curtiss R 3rd, McCoy KD, Macpherson AJ. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010; 328: 1705-9.
  2. Macpherson AJ, Slack E, Geuking MB, McCoy KD. The mucosal firewalls against commensal intestinal microbes. Semin Immunopathol. 2009; 31: 145-9.
  3. Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MA, Geuking MB, Beutler B, Tedder TF, Hardt WD, Bercik P, Verdu EF, McCoy KD, Macpherson AJ. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science. 2009; 325: 617-20.
  4. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol. 2008 Jan;1(1):11-22.
  5. McCoy KD, Stoel M, Stettler R, Merky P, Fink K, Senn BM, Schaer C, Massacand J, Odermatt B, Oettgen HC, Zinkernagel RM, Bos NA, Hengartner H, Macpherson AJ, Harris NL. Polyclonal and specific antibodies mediate protective immunity against enteric helminth infection. Cell Host Microbe. 2008 Oct 16;4(4):362-73
  6. Heikenwalder M, Prinz M, Zeller N, Lang KS, Junt T, Rossi S, Tumanov A, Schmidt H, Priller J, Flatz L, Rülicke T, Macpherson AJ, Holländer GA, Nedospasov SA, Aguzzi A. Overexpression of lymphotoxin in T cells induces fulminant thymic involution. Am J Pathol. 2008 Jun;172(6):1555-70.
  7. Fink K, Zellweger R, Weber J, Manjarrez-Orduno N, Holdener M, Senn BM, Hengartner H, Zinkernagel RM, Macpherson AJ. Long-term maternal imprinting of the specific B cell repertoire by maternal antibodies. Eur J Immunol. 2008 Jan;38(1):90-101.
  8. Macpherson AJ, Slack E. The functional interactions of commensal bacteria with intestinal secretory IgA. Curr Opin Gastroenterol. 2007 Nov;23(6):673-8.
  9. Macpherson AJ, McCoy K. APRIL in the intestine: a good destination for immunoglobulin A(2). Immunity. 2007 Jun;26(6):755-7.
  10. Macpherson AJ, Hapfelmeier S, McCoy KD. The armed truce between the intestinalmicroflora and host mucosal immunity. Semin Immunol. 2007 Apr;19(2):57-8.
  11. Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol. 2007 Apr;19(2):59-69.
  12. Pabst O, Herbrand H, Friedrichsen M, Velaga S, Dorsch M, Berhardt G, Worbs T, Macpherson AJ, Förster R. Adaptation of solitary intestinal lymphoid tissue in response to microbiota and chemokine receptor CCR7 signaling. J Immunol. 2006 Nov15;177(10):6824-32.
  13. Harris NL, Spoerri I, Schopfer JF, Nembrini C, Merky P, Massacand J, Urban JF Jr, Lamarre A, Burki K, Odermatt B, Zinkernagel RM, Macpherson AJ. Mechanisms of neonatal mucosal antibody protection. J Immunol. 2006 Nov 1;177(9):6256-62.
  14. Macpherson AJ. IgA adaptation to the presence of commensal bacteria in the intestine. Curr Top Microbiol Immunol. 2006;308:117-36.
  15. Mueller C, Macpherson AJ. Layers of mutualism with commensal bacteria protect us from intestinal inflammation. Gut. 2006 Feb;55(2):276-84.
  16. Macpherson AJ, Smith K. Mesenteric lymph nodes at the center of immune anatomy. J Exp Med. 2006 Mar 20;203(3):497-500.
  17. McCoy KD, Harris NL, Diener P, Hatak S, Odermatt B, Hangartner L, Senn BM, Marsland BJ, Geuking MB, Hengartner H, Macpherson AJ, Zinkernagel RM. Natural IgE production in the absence of MHC Class II cognate help. Immunity. 2006 Mar;24(3):329-39.
  18. Stecher B, Macpherson AJ, Hapfelmeier S, Kremer M, Stallmach T, Hardt WD. Comparison of Salmonella enterica serovar Typhimurium colitis in germfree mice and mice pretreated with streptomycin. Infect Immun. 2005 Jun;73(6):3228-41.
  19. Macpherson AJ, Geuking MB, McCoy KD. Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology. 2005 Jun;115(2):153-62.
  20. Macpherson AJ, Uhr T. Compartmentalization of the mucosal immune responses to commensal intestinal bacteria. Ann N Y Acad Sci. 2004 Dec;1029:36-43.
  21. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004 Jun;4(6):478-85.
  22. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004 Mar 12;303(5664):1662-5.

Dr. John Marshall

  1. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM; Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010; 59: 605-11.
  2. Thabane M, Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Collins SM, Salvadori M, Marshall JK. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010; 105: 933-9.
  3. Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology. 2010; 138: 1727-36.
  4. Narula N, Vasudev M, Marshall JK. IgG(4)-Related Sclerosing Disease: A Novel Mimic of Inflammatory Bowel Disease. Dig Dis Sci. 2010 [Epub ahead of print] PubMed PMID: 20521111.
  5. Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Patient outcomes after anti TNF-alpha drugs for Crohn's disease. Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 163-75.
  6. Narula N, Yamamura DL, Marshall JK. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can J Gastroenterol. 2010; 24: 121-5.
  7. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010; (1): CD004115.
  8. Marshall JK. Preventing post-surgical recurrence of Crohn’s disease: can we do better? (Journal Scan). Gut 2009; 58: 126.

  9. Marshall JK. Top-down prevention of post-surgical recurrence (Journal Scan). Gut 2009; 58: 294.
  10. Marshall JK. Post-infectious irritable bowel syndrome following water contamination. Kidney Int 2009; 75: S42-3.

  11. Marshall JK. TNF suppression is good to the bone (Journal Scan). Gut 2009; 58: 703.
  12. Dupuis M, Marshall JK, Hayes SM, Cytryn K, Murray S. Assessing the educational needs of Canadian gastroenterologists and gastroenterology nurses: challenges to optimal care in Crohn's Disease. Can J Gastroenterol. 2009; 23: 805-10.
  13. Marshall JK. Myocardial infarction, peptic ulcer and acetylsalicylic acid: of good and evil. Can J Gastroenterol. 2009; 23: 618.

  14. Kottachchi D, Yung D, Marshall JK. Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. Can J Gastroenterol. 2009; 23: 613-7.
  15. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009; 15: 3591-6.
  16. Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol. 2009; 104: 2267-74.
  17. Marshall JK. Post-infectious irritable bowel syndrome following water contamination. Kidney Int Suppl. 2009; 112: S42-3.
  18. Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JME, Marshall JK, Van Bebber S, Phillips KA. How do physician expectations of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated choice survey. Health Econ 2009; 18: 1420-39.
  19. Anvari M, Allen CJ, Marshall J, Armstrong D, Goeree R, Ungar W, Goldsmith C.  A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: one-year follow-up.  Surg Innov 2008; 13: 238-49 .
  20. Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Dieleman LA, Enns R, Franchimont D, Greenberg G, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Ropeleski M, Seidman E, Steinhart AH. The use of infliximab in ulcerative colitis: systematic review and implications for clinical practice. Can J Gastroenterol 2008; 22: 261-72.
  21. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P, Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-41.
  22. Marshall JK, Adams PA. The irritable infection. Can J Gastroenterol 2008; 22: 669-70.
  23. Marshall JK. Azathioprine, infliximab, certolizumab and adalimumab are effective for maintaining remission in Crohn’s disease. ACP J Club 2008; 148: 9.
  24. Marshall JK. Azathioprine, infliximab, certolizumab and adalimumab are effective for maintaining remission in Crohn’s disease. Evidence Based Med 2008; 13: 115.
  25. Marshall JK. Top-down use of infliximab (Journal Scan). Gut 2008; 57: 673.
  26. Marshall JK. Colectomy in ulcerative colitis: up the volume (Journal Scan). Gut 2008; 57: 837.
  27. Marshall JK. The compromised host (Journal Scan). Gut 2008;57:1139.
  28. Marshall JK. Concomitant immunosuppression on biological treatment: the debate continues (Journal Scan). Gut 2008; 57: 1298.
  29. Marshall JK: Concomitant immunosuppressives with biologic therapies: Pro. Gastrospectives 2008; 2: 4-5.
  30. Marshall JK. Gastroenteritis, irritable bowels and inflammatory bowel disease (Journal Scan). Gut 2008; 57: 1721.
  31. Marshall JK. Are there epidemiologic differences between Crohn’s disease and ulcerative colitis? Inflamm Bowel Dis 2008; 14: S1.
  32. Marshall JK. Perianal Crohn’s disease is carbon-friendly (Journal Scan). Gut 2008; 57: 1455.
  33. Comay D, Blackhouse G, Goeree R, Marshall JK. Photodynamic therapy for Barrett’s esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol 2007; 21: 217-22.
  34. Marshall JK, Thabane M, Borgaonkar M, James C. Post infectious irritable bowel syndrome following a foodborne outbreak of acute gastroenteritis attributed to a viral pathogen.  Clin Gastroenterol Hepatol 2007; 5: 457-60.
  35. Canadian Agency for Drugs and Technologies in Health. Evidence for PPI use in gastroesophageal reflux disease, dyspepsia and peptic ulcer disease: scientific report. Optimal Therapy Report – COMPUS 2007; 1. Available: http://www.cadth.ca/index.php/en/compus/ current-topics/ppis (accessed April 23 2007). Marshall JK – Member, COMPUS Expert Review Panel on PPIs.
  36. Canadian Agency for Drugs and Technologies in Health. Economic models and conclusions for the treatment of dyspepsia, gastroesophageal reflux disease-related heartburn and the prevention of non-steroidal anti-inflammatory drug induced gastrointestinal complications. Optimal Therapy Report – COMPUS 2007; 1. Available: http://www.catch.ca/index.php/en/compus/current-topics/ppis (accessed April 23 2007). Marshall JK – Member, COMPUS Expert Review Panel on PPIs.
  37. Thabane M, Kottachchi D, Marshall JK. Systematic review and meta-analysis to determine incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 15: 535-44.
  38. Leonard J, Marshall JK, Moayyedi P.  Systematic review of the risk of enteric infection in patients taking acid suppression.  Am J Gastroenterol 2007; 102: 2047-56.
  39. Marshall DA, Johnson FR, Phillips KA, Marshall JK, Thabane L, Ozdemir S, Kulin NA.  Measuring preferences for colorectal cancer screening using choice-format stated preferences.  Value Health 2007; 10: 415-30.
  40. Marshall JK. Cancer risk in patients with ulcerative colitis: a meta-analysis. Gastrospectives 2007; 1: 1-7.
  41. Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ.  Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and health impact.  Inflamm Bowel Dis 2006; 12: 38-46.
  42. Garg AX, Marshall JK, Salvadori M, Thiessen HR, MacNab J, Suri RS, Haynes RB, Pope J, Clark W. A gradient of acute gastroenteritis to assess risk of long-term health sequelae after drinking bacteria contaminated water. J Clin Epidemiol 2006; 59: 421-8.
  43. Borgaonkar MR, Ford D, Marshall JK, Churchill B, Collins SM. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 2006; 51: 1026-32.
  44. Marshall JK, Thabane M, James C. Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate. Dig Dis Sci 2006; 51: 864-8.
  45. Marshall JK, Thabane M, Garg AX, Clark W, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131: 445-50.
  46. Marshall JK.  Reporting ileocolonoscopy in inflammatory bowel disease.  Can J Gastroenterol 2006; 20: 399-400.
  47. Marshall JK. Finding inflammatory bowel disease genes will not lead to a cure.  Can J Gastroenterol 2006; 20: 643-4.
  48. Armstrong D, Marshall JK, Chiba N, Enns R, Fallone C, Fass R, Hollingworth R, Hunt R, Kahrilas P, Mayrand S, Moayyedi P, Paterson W, Sadowski D, van Zanten S. Canadian consensus conference on the management of gastroesophageal reflux in adults: update 2004. Can J Gastroenterol 2005: 19: 15-35.
  49. Garg A, MacNab J, Haynes M, Clark W, Marshall JK, Devereaux PJ, Suri R, Ray J. Long-term health sequelae following water contaminated with Escherichia coli 0157:H7 and Campylobacter species: population sampling and assessing non-participation biases. Can J Public Health 2005; 96: 125-30.
  50. Garg AX, Moist L, Matsell D, Thiessen-Philbrook HR, Haynes RB, Suri RS, Salvadori M, Ray J, Clark W, Walkerton Health Study Investigators. Risk of hypertension and reduced kidney function after acute gastroenteritis from bacteria-contaminated drinking water. Can Med Assoc J 2005; 173: 261-8.
  51. Garg AX, Clark W, Salvadori M, MacNab J, Suri RS, Haynes RB, Matsell D, Walkerton Health Study Investigators. Microalbuminuria 3 years after recovery from E. coli 0157 hemolytic uremic syndrome due to municipal water contamination. Kid International 2005; 67: 1476-82.
  52. Marshall JK, Gadowsky SL, Childs A, Armstrong D. Economic analysis of home versus hospital-based parenteral nutrition in Ontario, Canada. J Parent Enteral Nutr 2005; 29: 266-9.
  53. Tu Y, Salim S, Bourgeois J, Di Leo V, Irvine EJ, Marshall JK, Perdue MH.   CD23-mediated IgE transport across human intestinal epithelium: inhibition by blocking sites of translation or binding.  Gastroenterology 2005; 129: 928-40.
  54. Bensoussan K, Fallone CA, Barkun AN, Martel M, RUGBE Investigators.  A sampling of Canadian practice in managing nonvariceal upper gastrointestinal bleeding prior to recent guideline publication: is there room for improvement?  Can J Gastroenterol 2005; 19: 487-95.
  55. Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O’Brien BJ, Levy AR.  The impact of reference pricing of non-steroidal anti-inflammatory agents on the use and costs of analgesic drugs.  Health Serv Res 2005; 40: 1297-317.
  56. Greenwald E, Rawlinson J, Marshall JK. A distinctive case of dysphagia. Can Med Assoc J 2004; 170: 42.
  57. Marshall JK, Cawdron R, Zealley I, Riddell RH, Somers S, Irvine EJ.  Prospective comparison of small bowel meal with pneumocolon versus ileoscopy for diagnosis of ileal Crohn’s disease.  Am J Gastroenterol 2004; 99: 1321-9.
  58. Panaccione R, Fedorak RN, Aumais G, Bernstein C, Bitton A, Croitoru K, Enns R, Feagan B, Fisher M, Gelly A, Greenberg G, Griffiths A, Marshall JK, et al.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of infliximab in Crohn’s disease.  Can J Gastroenterol 2004; 18: 503-8.
  59. Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak R, Rahme E, Toubouti Y, Martel M, Chiba N, Fallone CA, RUGBE Investigators. The Canadian registry on non-variceal bleeding and endoscopy: endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-46
  60. Barkun A, Fallone CA, Chiba N, Fishman M, Flook N, Martin J, Rostom A, Taylor A, Nonvariceal Upper GI Bleeding Consensus Group.  A Canadian clinical practice algorithm for the management of patients with nonvariceal upper gastrointestinal bleeding. Can J Gastroenterol 2004; 18: 605-9
  61. Marshall JK, Thabane M, Garg AX, Meddings J, Clark W, Collins SM, WEL Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20: 1317-22.
  62. Marshall JK. Talk is cheap: the impact of consultation. Can J Gastroenterol 2004; 18: 181-2.

Dr. Ramona McLoughlin

  1. Sebastian SS, McLoughlin R, Qasim A, et al. Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia (watermelon stomach): long-term results. Digestive and Liver Disease 2004;36:212-217
  2. McNamara D, Mc Loughlin R, O’Morain C. Screening for colorectal cancer. Modern Medicine. 2004;34(4):19-28
  3. Mc Loughlin R, Racz I, Buckley M, O’Connor HJ, O’Morain C. Therapy of Helicobacter pylori. Helicobacter 2004;9(Supp 1):42-48
  4. Ryan AW, Thornton JM, Brophy K, Daly JS, O’Morain C, Mc Loughlin RM, et al. Haplotype variation at the IBD5 locus (5q31) in celiac disease in the Irish population. Tissue Antigens. 2004 Aug;64(2):195-8
  5. Mc Loughlin RM, O’Morain C. Effectiveness of Antiinfectives. Chemotherapy 2005. 51(5):243-6
  6. Raghunath AS, C O’Morain, McLoughlin RM. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005;22(suppl 1) 55-63.
  7. Mc Loughlin RM, O’Morain CA, O’Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundamental & Clinical Pharmacology 2005;19:421-427
  8. Stevens FM, McLoughlin RM. Is celiac disease a potentially treatable cause of liver failure? European Journal of Gastroenterology and Hepatology. 2005;10:1015-7
  9. Brophy K, Ryan AW, Thornton JM, Abouzakok M, Fitzgerald AP, Mc Loughlin RM, et al. Haplotypes in the CTLA4 region are associated with celiac disease in the Irish population. Genes Immun 2006;7(1):19-26
  10. Mc Loughlin RM, O’Morain CA. Colorectal Cancer Screening. World Journal of Gastroenterology World J Gastroenterol. 2006 Nov 14;12(42):6747-5

Professor Paul Moayyedi

  1. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt L, Quigley EM.  The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review.  Gut 2010; 59: 325-32.
  2. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010; 59: 605-11.
  3. Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010; 7: CD005415.
  4. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in irritable bowel syndrome. Aliment Pharmacol Ther. 2010; 32: 144-58.
  5. Laine L, Spiegel B. Rostom A. Moayyedi P. Kuipers EJ. Bardou M. Sung J. Barkun AN. Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference.  American Journal of Gastroenterology 2010; 105: 540-50.
  6. Ford AC, Moayyedi P. "Power" of Selective Serotonin Reuptake Inhibitors in Irritable Bowel Syndrome. Clin Gastroenterol Hepatol. 2010; 8: 313-4.
  7. Moayyedi P, Ford AC, Quigley EM, Foxx-Orenstein AE, Chey WD, Talley NJ, Brandt LJ. The American College of Gastroenterology irritable bowel syndrome monograph: translating systematic review data to clinical practice. Gastroenterology. 2010; 138: 789-91.
  8. Chey WD, Moayyedi P. Passing the Torch: The American Journal of Gastroenterology 2010.  American Journal of Gastroenterology 2010; 105: 4-7.
  9. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010; 152:101-13.
  10. Cameron C, Van Zanten SV, Skedgel C, Flowerdew G, Moayyedi P, Sketris I. Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking non-selective non-steroidal anti-inflammatory agents. Aliment Pharmacol Ther. 2010; 31: 1354-64.
  11. Ford AC, Thabane M, Collins SM, Moayyedi P, Garg AX, Clark WF, Marshall JK. Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: Cohort Study. Gastroenterology. 2010; 138: 373-8.
  12. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK. Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis. Gastroenterology. 2010; 138: 1502-13.
  13. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010; 105: 65-73.
  14. Ford AC, Guyatt GH, Talley NJ, Moayyedi P. Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol. 2010; 105: 280-8.
  15. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic Review and Meta-Analysis of the Prevalence of Irritable Bowel Syndrome in Individuals With Dyspepsia. Clin Gastroenterol Hepatol. 2010; 8: 401-9.
  16. Chow CK., Moayyedi P, Devereaux PJ. Is it safe to use a proton pump inhibitor with clopidogrel? Polskie Archiwum Medycyny Wewnetrznej 2009; 119: 564-8.
  17. Ford AC, Moayyedi P.  Managing dyspepsia.  Current Gastroenterology Reports 2009; 11: 288-94.

  18. Ford AC, Moayyedi P. Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care? Polskie Archiwum Medycyny Wewnetrznej 2009; 119: 391-6.
  19. Ford AC, Talley NJ, Quigley EM, Moayyedi P. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2009; 52: 1805.
  20. Ford AC, Moayyedi P. Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med. 2009; 151: 513.
  21. Ford AC, Moayyedi P. Bran and irritable bowels. Bran's deleterious effects: much ado about nothing. BMJ. 2009 Sep 29;339:b3956. doi: 10.1136/bmj.b3956. PubMed PMID: 19808815.
  22. Ford AC, Talley NJ, Moayyedi P. 10-biomarker algorithm to identify irritable bowel syndrome. Aliment Pharmacol Ther. 2009; 30: 95-6.
  23. Moayyedi P, Malfertheiner P. Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol. 2009; 104: 3081-3.
  24. Ford AC, Moayyedi P.  Treatment of chronic gastro-oesophageal reflux.  BMJ 2009; 339:b2481

  25. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 1279-86.
  26. Ford AC, Ching E, Moayyedi P. Meta-analysis: Yield of Diagnostic Tests for Coeliac Disease in Dyspepsia. Aliment Pharmacol Ther. 2009 Mar 27. [Epub ahead of print] PubMed PMID: 19416130.
  27. Moayyedi P, Sadowski DC. Proton pump inhibitors and clopidogrel – hazardous drug interaction or hazardous interpretation of data?. Can J Gastroenterol. 2009; 23: 251-2.
  28. Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009; 169: 651-8.
  29. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14: 7361-70.
  30. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt L, Quigley EM. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2008 on line first.
  31. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008 Nov 13;337:a2313. doi: 10.1136/bmj.a2313.
  32. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gut. 2009; 58: 367-78
  33. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel DL, Moayyedi P. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008; 300: 1793-805
  34. Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P. Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut 2008; 57: 1545-53.
  35. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Alimentary Pharmacology and Therapeutics 2008; 28: 1013-20.
  36. Ford AC, Moayyedi P, Jarbol DE, Logan RFA, Delaney BC. Meta-analysis: H. pylori"test and treat" compared with empirical acid suppression for managing dyspepsia? Alimentary Pharmacology and Therapeutics 2008; 28: 534-44
  37. Das D., Ishaq S., Harrison R., Kosuri K., Harper E., Decaestecker J., Sampliner R., Attwood S., Barr H., Watson P., Moayyedi P., Jankowski J. Management of Barrett’s esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. American Journal of Gastroenterology 2008; 103:1079-89.
  38. Ford AC., Forman D., Bailey AG, Axon AT., Moayyedi P. Irritable bowel syndrome: a 10 year natural history of symptoms and factors that influence consultation behaviour. American Journal of Gastroenterology 2008; 103: 1229-39
  39. Barton PM., Moayyedi P., Talley NJ., Vakil NB., Delaney BC. Cost effectiveness analysis: applications. Medical Decision Making 2008; 28: 33-43.
  40. Tse F., Liu L., Barkun AN., Armstrong D., Moayyedi P. EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointestinal Endoscopy 2008; 67:235-44.
  41. Delaney BC., Qume M., Moayyedi P., Logan RF., Ford AC., Elliott C., McNulty C., Wilson S., Hobbs FD. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomized controlled trial (MRC-CUBE trial). BMJ 2008; 336: 651-4.
  42. Barton PM. Moayyedi P., Talley NJ., Vakil NB., Delaney BC. A second-older simulation model of the cost-effectiveness of managing dyspepsia in the United States. Medical Decision Making 2008; 28: 44-45.
  43. Moayyedi P., Burch N., Akhtak-Danesh N., Enaganti SK., Harrison R., Talley NJ., Jankowski J. Mortality rates in patients with Barrett’s esophagus. Alimentary Pharmacology and Therapeutics 2008; 27: 316-20.
  44. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD003244. DOI: 10.1002/14651858.CD003244.pub2.
  45. Leontiadis GI., Sreedharan A., Dorward S., Barton P., Delaney B., Howden CW., Orhewere M., Gisbert J., Sharma VK., Rostom A., Moayyedi P., Forman D. Systematic reviews of the clinical effectiveness and cost effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Heath Technology Assessment 2007; 11: 1-51.
  46. Ford, AC., Forman D., Nathan J., Crocombe WD., Axon ATR., Moayyedi P. Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. Aliment Pharmacol Ther 2007: 26; 1267-1275.
  47. Fraser A. Delaney BC. Ford AC. Qume M. Moayyedi P. The Short-Form Leeds Dyspepsia Questionnaire validation study. Alimentary Pharmacology & Therapeutics 2007; 25: 477-86.
  48. Leonard J. Marshall JK. Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. American Journal of Gastroenterology 2007; 102: 2047-56.
  49. Hilsden RJ. Tepper J. Moayyedi P. Rabeneck L. Who provides gastrointestinal endoscopy in Canada? Canadian Journal of Gastroenterology 2007; 21: 843-6.
  50. Harrison R. Perry I. Haddadin W. McDonald S. Bryan R. Abrams K. Sampliner R. Talley NJ. Moayyedi P. Jankowski JA. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. American Journal of Gastroenterology 2007; 102: 1154-61.
  51. Ford AC. Forman D. Bailey AG. Cook MB. Axon AT. Moayyedi P. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. American Journal of Gastroenterology 2007; 102: 957-65.
  52. Moayyedi P. Tepper J. Hilsden R. Rabeneck L. International comparisons of manpower in gastroenterology. American Journal of Gastroenterology 2007; 102: 478-81.
  53. Ford AC. Forman D. Bailey AG. Axon AT. Moayyedi P. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut 2007; 56: 321-7.
  54. Ford, A., Forman, D., Bailey, A., Goodman, K., Axon, A., Moayyedi, P. Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. International Journal of Epidemiology 2007: 36; 1327-1333.
  55. Moayyedi P., Talley, N., Fennerty MB., Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA 2006; 295: 1566-76
  56. Moayyedi P., Achkar E. Does fecal occult blood testing really reduce mortality? A reanalysis of systematic review data. American Journal of Gastroenterology 2006; 101: 380-384.
  57. Dorward S. Sreedharan A. Leontiadis GI. Howden CW. Moayyedi P. Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database of Systematic Reviews. (4):CD005415, 2006
  58. Ford AC. Forman D. Moayyedi P. Morice AH. Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. Thorax 2006; 61: 975-9.
  59. Vakil N. Moayyedi P. Fennerty MB. Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006; 131: 390-401.
  60. Jankowski J., deCaestecker J., Harrison R., Watson P., Barr H., Attwood S., Moayyedi P., NSAID and esophageal adenocarcinoma: randomised trials needed to correct for bias. Lancet Oncology 2006; 7: 7-8.
  61. Ford, AC., Forman D., Bailey AG., Axon ATR., Moayyedi P. A Community Screening and Treatment Program for Helicobacter pylori Saves Money: Ten-year Follow-up of a Randomized Controlled Trial. Gastroenterology 2005; 129: 1900-1909.
  62. Ford AC., Qume M., Moayyedi P., Arents NL,. Lassen AT., Logan RF., McColl KE., Myres P., Delaney BC. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005; 128: 1838-44.
  63. Talley NJ., Vakil NB., Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-80.
  64. Ford AC., Forman D., Reynolds PD., Cooper B., Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. American Journal of Epidemiology 2005; 162: 454-60.
  65. Mahadeva S., Raman MC., Ford AC., Follows M., Axon ATR., Goh KL., Moayyedi P. Gastroesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. Alimentary Pharmacology and Therapeutics 2005; 21: 1483-90.
  66. Donnellan C., Sharma N., Preston C., Moayyedi P. Medical treatments for the maintenance therapy of reflux esophagitis and endoscopic negative reflux disease. Cochrane Database of Systematic Reviews. (2):CD003245, 2005
  67. Fraser A., Delaney B., Moayyedi P. Symptom-based outcome measures for dyspepsia and GERD trials: A systematic review. American Journal of Gastroenterology 2005; 100: 442-452.
  68. Mason JM. Delaney B. Moayyedi P. Thomas M. Walt R. North of England Dyspepsia Guideline Development Group. Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales. Alimentary Pharmacology & Therapeutics 2005; 21: 1135-43.
  69. Moayyedi P., Forman D., Duffett S., Mason S., Brown J., Crocombe W., Feltbower R, Axon ATR on behalf of the Leeds HELP study group. The association between Helicobacter pylori infection and adult height. European Journal of Epidemiology 2005; 20: 455-65.
  70. Cremonini F., Wise J., Moayyedi P., Talley N. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta analysis. American Journal of Gastroenterology 2005; 100: 1226-1232.
  71. Jankowski J., Moayyedi P. Cost effectiveness of aspirin chemoprevention for Barrett’s esophagus. Journal of the National Cancer Institute 2004; 96: 885-887.
  72. Soo S., Forman D., Delaney B., Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. American Journal of Gastroenterology 2004; 99: 1817-1822.
  73. Ford A., Delaney B., Forman D., Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. American Journal of Gastroenterology 2004; 99: 1833-1855.
  74. Moayyedi P., Delaney B., Vakil N., Forman D., Talley N. The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329-37.
  75. Delaney B., Moayyedi P., Forman D., Helicobacter pylori infection. Clinical Evidence 2004 : 641-58.
  76. Steele RJC, Gnauck R, Hrcka R, Kronborg O, Kuntz C, Moayyedi P, O’Morain C. Spicak J, Vainio H. Methods and economic considerations: Group 1 report. Endoscopy 2004; 349-353.
  77. Dent J., Armstrong D., Delaney B., Moayyedi P., Talley J., Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004; 53: 1-24.
  78. Sharma N., Donnellan C., Preston C., Delaney B,. Duckett G., Moayyedi P. A systematic review of symptomatic outcomes used in esophagitis drug therapy trials. Gut 2004; 53: 58-65.
  79. Abraham NS., Moayyedi P., Daniels B., Veldhuyzen Van Zanten SJO. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Alimentary Pharmacology and Therapeutics. 2004; 19: 631-641.
  80. Sreedharan A., Clough M., Hemingbrough E., Gatta L., Chalmers DM., Axon ATR., Moayyedi P. Cost-effectiveness and long-term impact of Helicobacter pylori 'test and treat' service in reducing open access endoscopy referrals. European Journal of Gastroenterology & Hepatology 2004; 16: 981-6.
  81. Ford A., Delaney B., Forman D., Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients (Cochrane Review). In: The Cochrane Library, Issue 1, 2004, Chichester, UK: John Wiley & Sons, Ltd.
  82. Moayyedi, P. Sequential regimens for Helicobacter pylori eradication. The Lancet 2007: 370; 1010-1012.
  83. Moayyedi P. The promises and perils of nurse-led flexible sigmoidoscopy screening. Canadian Journal of Gastroenterology 2007; 21: 280-2.
  84. Moayyedi, P. Colorectal cancer screening lacks evidence of benefit. Cleveland Clinic Journal of Medicine 2007: 74; 545-554.
  85. Moayyedi P., Clues to the etiology of inflammatory bowel disease – a return to John Snow? American Journal of Epidemiology; 2006:164;624-626.
  86. Moayyedi P., Helicobacter pylori test-and-eradicate strategy versus early endoscopy in patients with dyspepsia. Nature Clinical Practice Gastroenterology & Hepatology 2005; 2: 70-71.
  87. Moayyedi P., Talley NJ. Gambling with gastroesophageal reflux disease: should we worry about the QALY? American Journal of Gastroenterology 2005; 100: 534-6.
  88. Moayyedi P., Delaney B. Measuring gastroesophagel reflux symptoms: Musings from Marrakech. American Journal of Gastroenterology 2005; 100: 19-20.
  89. Moayyedi P. Should patients with GERD be screened once at least for Barrett’s epithelium? Con: Patients with GERD should be screened once at least for Barrett’s esophagus – Medicine or magic? American Journal of Gastroenterology 2004; 99: 2293-4.
  90. Delaney B., Moayyedi P. Eradicating H. pylori. Does not increase symptoms of gastro-esophageal reflux disease. British Medical Journal 2004; 328: 1388-9.
  91. Moayyedi P. Bringing science to the art of diagnosis. Gut 2004; 53: 627-628.
  92. Modlin IM., Hunt RH., Malfertheiner P., Moayyedi P., Quigley EM., Tytgat GNJ., Tack J., Holtmann G., Moss SF. Non-erosive reflux disease – defining the entity and delineating the management. Digestion 2008;78(suppl 1):1-5.
  93. Moayyedi P. Economic reflections on proton pump inhibitor therapy for non-erosive reflux disease. Digestion 2008; 78(suppl 1): 61-69.
  94. Moayyedi P. The epidemiology of obesity and gastrointestinal and other diseases: An overview. Digestive Diseases and Sciences 2008; 53: 2293-9.
  95. Dent J, Kahrilas PJ, Vakil N, Veldhuyzen van Zanten S, Bytzer P, Delaney B, Haruma K, Hatlebakk J, McColl E, Moayyedi P, Stanghellini V, Tack J, Vaezi M. Clinical trial design in adult reflux disease: a methodological workshop. Alimentary Pharmacology and Therapeutics 2008; 28: 107-26.
  96. Ford AC. Moayyedi P. Current guidelines for dyspepsia management. Digestive Diseases 2008; 26: 225-30.
  97. Tally NJ., Fock KM., Moayyedi P., Gastric cancer consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. American Journal of Gastroenterology 2008 103:510-4.
  98. Moayyedi P. Barrett’s esophagus and obesity: the missing part of the puzzle. American Journal of Gastroenterology 2008; 103: 301-3.
  99. Fock KM., Talley N., Moayyedi P., Hunt R., Azuma T., Sugano K., Xiao SD., Lam SK., Goh KL., Chiba T., Uemura N., Kim JG., Kim N., Ang TL., Mahachai V., Mitchell H., Rani AA., Liou JM., Vilaichone RK., Sollano J. Asia-Pacific Gastric Cancer Consensus Conference. Asia-Pacific consensus guidelines on gastric cancer prevention. Journal of Gastroenterology and Hepatology 2008; 23: 351-65.
  100. Moayyedi, P. Who pays the piper? Journal of Clinical Gastroenterology 2007:41(2); S97-S101.
  101. Moayyedi P. The health economics of Helicobacter pylori infection. Best Practice & Research in Clinical Gastroenterology 2007; 21: 347-61.
  102. Pare P. Bridges R. Champion MC. Ganguli SC. Gray JR. Irvine EJ. Plourde V. Poitras P. Turnbull GK. Moayyedi P. Flook N. Collins SM. Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Canadian Journal of Gastroenterology 2007; 21 Suppl B:3B-22B.
  103. Moayyedi P. Should triple therapy for Helicobacter pylori eradication be prescribed for 1 week or 2 weeks? Nature Clinical Practice Gastroenterology and Hepatology 2007:4(11);596-597.
  104. Moayyedi P., Talley NJ. Gastro-esophageal reflux disease. Lancet 2006; 367 : 2086-2100.
  105. Barr H. Kendall C. Bazant-Hegemark F. Moayyedi P. Shetty G. Stone N. Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. Medscape General Medicine 2006; 8: 66-88.
  106. Achkar R., Moayyedi P. Colorectal screening with fecal occult blood testing (FOBT): An international Perspective. American Journal of Gastroenterology 2006; 101: 212.
  107. Moayyedi P., Epidemiology of columnar-lined esophagus. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett’s columnar lined esophagus. August 2005 pages 7-9.
  108. Moayyedi P., Economic aspects of surveillance. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett’s columnar lined esophagus. August 2005 pages 37-39.
  109. Malfertheiner P., Sipponen P., Naumann M., Moayyedi, P. et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: A state-of-the-art- critique. American Journal of Gastroenterology 2005; 100: 2100-2115.
  110. Moayyedi P. Coût et efficacité du dépistage de Helicobacter pylori. La lettre de l’hepato- gastroentérologue 2005; 8: 126-29.
  111. Moayyedi P., Axon AT. Review article: gastro-esophageal reflux disease--the extent of the problem. Alimentary Pharmacology & Therapeutics 2005; 22 (suppl 1): 11-9.
  112. Moayyedi, P. Should we test for Helicobacter pylori before treating gastroesophageal reflux disease. Canadian Journal of Gastroenterology 2005; 19: 425-29.
  113. Bourke B., Ceponis P., Chiba N., Czinn S., Ferraro R., Fischbach L., Gold B., Hyunh H., Jacobson K., Jones NL., Koletzko S., Lebel S., Moayyedi P., Ridell R., Sherman P., van Zanten S., Beck I., Best L., Boland M., Bursey F., Chaun H., Cooper G., Craig B., Creuzenet C., Critch J., Govender K., Hassall E., Kaplan A., Keelan M., Noad G., Robertson M., Smith L., Stein M., Taylor D., Walters T., Persaud R., Whitaker S., Woodland R., Canadian Helicobacter Study Group. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Canadian Journal of Gastroenterology 2005; 19: 399-408.
  114. Armstrong D., Marshall J., Chiba N., Enns R., Fallone C., Fass R., Hollingworth R., Hunt R., et al. Canadian consensus conference on the management of gastroesophageal reflux disease in adults – update 2004. Canadian Journal of Gastsroenterology 2005; 19: 15-35.
  115. Moayyedi P. Meta-analysis: can we mix apples and oranges? American Journal of Gastroenterology 2004; 99: 2297-301.
  116. Chiba N., Gralnek I., Moayyedi P., Provenzale D., Inadomi J., Willan A., Briggs A., Kim W. A glossary of economic terms. European Journal of Gastroenterology & Hepatology 2004; 16: 563-565.
  117. Moayyedi P., Delaney B. What a difference a datum makes. Gastroenterology 2004; 127: 1007-1008.
  118. Moayyedi P., Hunt R., Helicobacter pylori public health implications. Helicobacter 2004; 9(suppl 1): 67-72
  119. Moayyedi P., Duffy J., Delaney B. New approaches to enhance the accuracy of the diagnosis of reflux disease. Gut 2004; 53: 55-57.
  120. Chey WD., Moayyedi P. Review article: uninvestigated dyspepsia and non-ulcer dyspepsia – the use of endoscopy and the roles for Helicobacter pylori eradication and antisecretory therapy. Alimentary Pharmacology & Therapeutics 2004; 19 (suppl 1): 1-8.
  121. Moayyedi P., Mason J. Cost utility and cost-benefit analyses: how did we get here and where are we going? European Journal of Gastroenterology and Hepatology 2004; 16: 527-34.

Professor David Morgan

  1. Bridges RJ, Paterson WG, Sinclair P, Morgan DG. Summary of the Canadian Association of Gastroenterology 2004 strategic plan. Can J Gastroenterol. 2010; 24: 164-72.
  2. Leddin D, Bridges RJ, Morgan DG, Fallone C, Render C, Plourde V, Gray J, Switzer C, McHattie J, Singh H, Walli E, Murray I, Nestel A, Sinclair P, Chen Y, Irvine EJ. Survey of access to gastroenterology in Canada: the SAGE wait times program. Can J Gastroenterol. 2010; 24: 20-5.
  3. Morgan DG, O'Mahony MF, O'Mahony WF, Roy J, Camacho F, Dinniwell J, Horbay GL, Husein-Bhabha FA; RAB-GRD-3002 Study Group. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Can J Gastroenterol. 2007; 21: 820-6.
  4. Leddin D, Hunt R, Champion M, Cockeram A, Flook N, Gould M, Kim YI, Love J, Morgan D, Natsheh S, Sadowski D, for the Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation committee on colon cancer screening: Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on Colon Cancer Screening. Can J Gastroenterol Vol. 18 No. 2:93-99 (2004).
  5. Morgan DG, Atin M, Aumais G, Cockeram A, Habal F, Switzer C, Wolman S: Increasing Versatility of PPIs: The Place of Orally Disintegrating Lansoprazole. The Canadian Journal of Diagnosis Vl. 23 No. 11:101-18(2006)

Dr. Trevor Seaton

  1. D Bair, J Pham, MB Seaton, N Arya, M Pryce, Seaton TL. The quality of screening colonoscopies in an office-based endoscopy clinic. Can J Gastroenterol 2009: 23: 41-47.

Dr. Robert Spaziani

  1. Spaziani R, Bayati A, Redmond K, Bajaj H, Mazzadi S, Bienenstock J, Collins SM, Kamath MV. Vagal dysfunction in irritable bowel syndrome assessed by rectal distension and baroreceptor sensitivity. Neurogastroenterol Motil. 2008;20:336-42.

Dr. Frances Tse

  1. Leontiadis GI, Tse F, Howden CW. Antiplatelet therapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. Key messages for clinical practice. Pol Arch Med Wewn. 2010; 120: 143-7.
  2. Radhi J, Tse F, Marcaccio M. Papillocystic variant of acinar cell pancreatic carcinoma. J Oncol. 2010; 2010: 242016. Epub 2010 Mar 3. PubMed PMID: 20204128.
  3. Tse F, Liu L, Barkun AN, Armstrong D, Moayyedi P. EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc 2008 Feb;67(2):235-44.
  4. Tse F, Romagnuolo J, Friedman G, Bornstein JD, Barkun JS, Barkun AN. Non-operative Imaging Techniques in Suspected Biliary Tract Obstruction. HBP 2006: 8 (6):409-4252.
  5. Tse F, Barkun JS, Barkun AN., The elective evaluation of patients with suspected choledocholithiasis undergoing laparoscopic cholecystectomy., Gastrointest Endosc. 2004 Sep;60(3):437-48.

Dr. Keith Tsoi

  1. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding?. Am J Med. 2006 Sep;119(9):719-27.

Dr. Helga Witt-Sullivan

  1. Zandieh, D, Krygier, V, Wong, J. Howard, L. Worobetz, G. Minuk, H. Witt-Sullivan, E. Yoshida. The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada: the CASL Experience
 
Can J Gastroenterol 2008;22(4):388-392